302 related articles for article (PubMed ID: 29801705)
1. Widespread Nivolumab-induced Enteropathy in a Long Responder Non-Small-cell Lung Cancer Patient.
Facchinetti F; Gnetti L; Caruana P; Fornaroli F; Luigi de'Angelis G; Sabato M; Ferri L; Cosenza A; Bordi P; Tiseo M
Clin Lung Cancer; 2018 Sep; 19(5):e591-e596. PubMed ID: 29801705
[No Abstract] [Full Text] [Related]
2. Late Gastrointestinal Toxicity During Nivolumab Therapy in Non-Small Cell Lung Cancer: A Rare Case of Inflammatory Bowel Disease.
Guaitoli G; Baldessari C; Tomasello C; Barbieri F; Cascinu S; Bertolini F; Cesinaro AM
J Thorac Oncol; 2018 Aug; 13(8):e152-e153. PubMed ID: 30049380
[No Abstract] [Full Text] [Related]
3. Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient.
Karakas Y; Yuce D; Kılıckap S
Oncol Res Treat; 2017; 40(10):621-622. PubMed ID: 28950270
[No Abstract] [Full Text] [Related]
4. Nivolumab-Induced Hemophilia A Presenting as Gastric Ulcer Bleeding in a Patient With NSCLC.
Kato R; Hayashi H; Sano K; Handa K; Kumode T; Ueda H; Okuno T; Kawakami H; Matsumura I; Kudo M; Nakagawa K
J Thorac Oncol; 2018 Dec; 13(12):e239-e241. PubMed ID: 30017828
[No Abstract] [Full Text] [Related]
5. Nivolumab-Induced Fulminant Immune-Related Colitis Despite Infliximab in a Patient With NSCLC.
Callens R; Tamsin A; van Zandweghe L
J Thorac Oncol; 2019 Mar; 14(3):e49-e50. PubMed ID: 30782382
[No Abstract] [Full Text] [Related]
6. Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.
Hida T
Ther Adv Respir Dis; 2018; 12():1753466618801167. PubMed ID: 30249170
[TBL] [Abstract][Full Text] [Related]
7. Eczematous reactions mimicking psoriasiform dermatitis induced by nivolumab for advanced lung cancer.
Tanaka M; Hoashi T; Ichiyama S; Noro R; Seike M; Kubota K; Gemma A; Funasaka Y; Saeki H
Australas J Dermatol; 2019 Feb; 60(1):e67-e68. PubMed ID: 29896926
[No Abstract] [Full Text] [Related]
8. Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab.
Noda-Narita S; Mizuno S; Noguchi S; Watanabe K; Nakai Y; Koike K; Kage H; Nagase T
Eur J Cancer; 2019 Jan; 107():93-96. PubMed ID: 30554074
[No Abstract] [Full Text] [Related]
9. Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy.
Fujita K; Kim YH; Kanai O; Yoshida H; Mio T; Hirai T
Respir Med; 2019 Jan; 146():66-70. PubMed ID: 30665520
[TBL] [Abstract][Full Text] [Related]
10. Response to "Immune-mediated cholangitis: is it always nivolumab's fault?".
Kashima J; Okuma Y
Cancer Immunol Immunother; 2018 Aug; 67(8):1329-1330. PubMed ID: 29700568
[No Abstract] [Full Text] [Related]
11. Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient.
Fragulidis G; Pantiora E; Michalaki V; Kontis E; Primetis E; Vezakis A; Polydorou A
J Oncol Pharm Pract; 2019 Mar; 25(2):487-491. PubMed ID: 29067858
[TBL] [Abstract][Full Text] [Related]
12. Severe infusion reaction due to nivolumab: A case report.
Kumari S; Yun J; Soares JR; Ding PN
Cancer Rep (Hoboken); 2020 Jun; 3(3):e1246. PubMed ID: 32671983
[TBL] [Abstract][Full Text] [Related]
13. [Fulminant myocarditis caused by nivolumab treatment for non-small cell lung cancer (NSCLC): a case report].
Tan KX; Li CY; Zhang JY; Cui HJ; Shen W; Zhang X; Sun CY; Jiang XJ; Zheng SY; Li J; Xue CX
Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):1047-1048. PubMed ID: 33342162
[No Abstract] [Full Text] [Related]
14. Fatal Necrotizing Encephalopathy after Treatment with Nivolumab for Squamous Non-Small Cell Lung Cancer: Case Report and Review of the Literature.
Leitinger M; Varosanec MV; Pikija S; Wass RE; Bandke D; Weis S; Studnicka M; Grinzinger S; McCoy MR; Hauer L; Sellner J
Front Immunol; 2018; 9():108. PubMed ID: 29441072
[TBL] [Abstract][Full Text] [Related]
15. Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.
Grossi F; Crinò L; Logroscino A; Canova S; Delmonte A; Melotti B; Proto C; Gelibter A; Cappuzzo F; Turci D; Gamucci T; Antonelli P; Marchetti P; Santoro A; Giusti S; Di Costanzo F; Giustini L; Del Conte A; Livi L; Giannarelli D; de Marinis F
Eur J Cancer; 2018 Sep; 100():126-134. PubMed ID: 30014881
[TBL] [Abstract][Full Text] [Related]
16. Immune-mediated cholangitis: is it always nivolumab's fault?
Gelsomino F; Vitale G; Ardizzoni A
Cancer Immunol Immunother; 2018 Aug; 67(8):1325-1327. PubMed ID: 29623342
[No Abstract] [Full Text] [Related]
17. New onset of psoriasis during nivolumab treatment for lung cancer.
Chujo S; Asahina A; Itoh Y; Kobayashi K; Sueki H; Ishiji T; Umezawa Y; Nakagawa H
J Dermatol; 2018 Mar; 45(3):e55-e56. PubMed ID: 29205470
[No Abstract] [Full Text] [Related]
18. Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program.
Baldini E; Lunghi A; Cortesi E; Turci D; Signorelli D; Stati V; Melotti B; Ricciuti B; Frassoldati A; Romano G; Ceresoli GL; Illiano A; Verderame F; Fasola G; Ricevuto E; Marchetti P; Pinto C; Cartenì G; Scotti V; Tibaldi C; Fioretto L; Giannarelli D
Lung Cancer; 2020 Feb; 140():59-64. PubMed ID: 31881412
[TBL] [Abstract][Full Text] [Related]
19. Recurrent Episodes of Nivolumab-Induced Pneumonitis after Nivolumab Discontinuation and the Time Course of Carcinoembryonic Antigen Levels: A Case of a 58-Year-Old Woman with Non-Small Cell Lung Cancer.
de Jong C; Peters BJM; Schramel FMNH
Chemotherapy; 2018; 63(5):272-277. PubMed ID: 30572331
[TBL] [Abstract][Full Text] [Related]
20. Stevens-Johnson syndrome during nivolumab treatment of NSCLC.
Salati M; Pifferi M; Baldessari C; Bertolini F; Tomasello C; Cascinu S; Barbieri F
Ann Oncol; 2018 Jan; 29(1):283-284. PubMed ID: 29045532
[No Abstract] [Full Text] [Related]
[Next] [New Search]